Endo’s Par Sterile Products business is offering premixed ephedrine sulfate injection in a ready-to-use 50 mg/10 ml single-use vial.
"We are pleased to launch this new ready-to-use product as part of our agreement with Nevakar," said Scott Sims, senior vice president and general manager, Sterile Products at Endo. "This is a demonstration of our commitment to deliver quality, life-enhancing therapies to healthcare providers — when and how they need them."
Ready-to-use products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow and heighten accuracy and compliance by reducing the chance for preparation error — all of which support quality patient care, the company said.
This is the first product launch under the previously announced exclusive licensing agreement between Nevakar Injectables, a privately held biopharmaceutical company, and Endo's subsidiary, Endo Ventures. Under the agreement, the companies are collaborating on five differentiated sterile injectable products in the United States.
Nevakar is responsible for developing the drugs and obtaining approval from the Food and Drug Administration, and EVL is responsible for product launch and distribution through Endo's Par Sterile Products business.
Lori Flees, senior vice president and chief operating officer of Walmart health and wellness, shared Friday on her LinkedIn page that she has left Walmart. Flees has been in her current position since August 2020.
“I cannot believe it but today is my last day at Walmart. It was not long after I joined the company in January 2014 that I started to drink the Kool-Aid (so to speak) and begin serving it to all my friends and family according to James, my husband. While the scale of Walmart is hard to get your mind around, it is the heart of Walmart that forever changes you. And the heart is the timeless mission (helping people save money and live better) and the associates who will do nearly anything to serve others and make their communities and the world a better place," Flees wrote.
Flees went on to thank all of the associates she worked with, stating, "you inspire me. Thank you to my teammates in corporate strategy, M&A, corp financial planning, store No. 8, strategic partnerships, Vudu, Sam’s health and wellness and Walmart health and wellness — we accomplished a lot due to your efforts and passion. Thank you to Walmart leaders I have collaborated with — you always made the solutions or the plan better. Thank you to my amazing supervisors who supported and invested in me. And thank you my mentees who contributed more to my development than I did theirs."
Flees added, "I look forward to watching the company continue to innovate for the benefit of customers and associates around the world as a loyal customer and shareholder."
The Food and Drug Administration has given USB its blessing for Fintepla (fenfluramine) oral solution CIV for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older.
Fintepla was developed by Zogenix, which was recently acquired by UCB.
The medication already is approved for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.
Additionally, the FDA granted Fintepla pediatric exclusivity.
LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-refractory seizures with high morbidity as well as serious impairment of neurodevelopmental, cognitive and motor functions. It affects an estimated 30,000 to 50,000 patients in the United States.
"The approval of Fintepla for Lennox-Gastaut syndrome highlights our continued commitment to bringing differentiated medicines to patients who may not be well controlled on current therapies, and their caregivers," Mike Davis, head of global epilepsy at UCB said. "We are proud to add Fintepla as a treatment for Dravet syndrome, and now Lennox-Gastaut syndrome, to our portfolio of epilepsy medicines to help reduce the impact and burden of seizures, including severe epilepsy syndromes that have high pediatric morbidity and mortality rates."
Fintepla for LGS is available through a restricted distribution program, called the Fintepla Risk Evaluation and Mitigation Strategy Program.
No Cow, maker of plant-based, low-sugar protein bars and powders, is adding a chocolate-dipped protein bar to its lineup. The Denver-based brand, which launched in 2015, offers gluten-, soy- and dairy-free products that are Non-GMO Project Verified, kosher and vegan.
The new Dipped bars use a proprietary blend of rice and pea protein and feature flavors reminiscent of classic American candies. The six flavors are: chocolate sea salt, chocolate salted caramel, chocolate peanut butter cup, chocolate mint cookie, chocolate sprinkled donut and chocolate coconut almond, the last being the signature flavor of country music star and No Cow brand ambassador Jessie James Decker.
Each bar contains 20 g of plant protein, 3 g to 5 g net carbs and 1 g of sugar.
“Forget about just trying to be the best plant-based option, we truly believe that the new line of Dipped Protein Bars are quite simply the best protein bars on the market, period,” said CEO Eric Haddenhorst. “Early feedback from both consumers and retail partners after a soft launch of two flavors could not have been stronger. Consumers love the taste of these new bars — so many have told us they can’t believe they are plant-based. Of course, they still expect all of the low sugar, high protein, low carb benefits that they’ve come to expect from No Cow.”
The brand’s offerings, which include 19 flavors of protein bars and two flavors of protein powder, are supported by investors that include General Mills’ 301, Valor Equity Partners and Loft Partners.
The single flavor 12-count boxes of the Chocolate Dipped line have a $29.99 SRP.
Dove is rolling out a new line of antiperspirants, dubbed Dove Ultimate Antiperspirant.
The company noted that the line is created with breakthrough water-based technology to help restore underarm skin to its best condition. The formula contains a high concentration of glycerin, which is supposed to soothe dryness and help improve texture, for soft and healthy-looking underarms.
Product highlights also include:
• Water-based technology;
• Glides more easily for a smooth, even feel;
• 6x more humectant moisturizers versus Dove Advanced Care;
• Proven to moisturize skin for longer; and
• 48 hour sweat & odor protection.
Dove Ultimate Antiperspirant is available in six scents: Peony & Rose Water, Cucumber Water & Mint, Coconut & Sandalwood, Jasmine & Vanilla, Orchid & Blackberry and Gardenia & Aloe.